Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704171 · ClinicalTrials.gov registry record · Phase 4
PleuraSeal Post Market Study (Europe)
A Phase 4 study, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 121
- Enrollment target
NCT00704171: Completed Phase 4 study, sponsored by Integra LifeSciences Corporation.
NCT00704171 is a Phase 4 study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 121 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00704171, a Phase 4 study, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 121 participants
- Enrollment target
Study Summary
To further characterize the PleuraSeal Sealant System as compared to standard of care (sutures and staples only) in subjects undergoing an elective pulmonary lobectomy and segmentectomy via open thoractomy.
Interventions
- PROCEDURE Standard Tissue Closure Techniques
- DEVICE PleuraSeal Lung Sealant System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
What the finished NCT00704171 record still lists
NCT00704171 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard Tissue Closure Techniques is the first listed.
NCT00704171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00704171 about?
NCT00704171 is a clinical study titled "PleuraSeal Post Market Study (Europe)". To further characterize the PleuraSeal Sealant System as compared to standard of care (sutures and staples only) in subjects undergoing an elective pulmonary lobectomy and segmentectomy via open thoractomy.
What is the current status of trial NCT00704171?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 121 participants. The study started on 2008-01. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00704171?
The interventions under investigation include: Standard Tissue Closure Techniques (PROCEDURE), PleuraSeal Lung Sealant System (DEVICE).
Who is sponsoring clinical trial NCT00704171?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00704171's enrollment target sits among peer trials
121 669th of 2000 higher than 1,328 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia